
Manufacturing changes - such as changes in formulation or source material - can impact a product’s immunogenicity.

Manufacturing changes - such as changes in formulation or source material - can impact a product’s immunogenicity.

Neutralization of therapeutic protein products does not produce an obvious clinical deficiency syndrome for all therapeutic protein products with endogenous counterparts, because many endogenous proteins are biologically redundant.

Published: November 1st 2004 | Updated: